Mostrando 2 resultados de: 2
Filtros aplicados
Subtipo de publicación
Article(2)
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
ArticleAbstract: The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucaPalabras claves:antidiabetic drug, Cardiovascular disease, Clinical trial, diabetes complications, GLP-1 receptor agonistAutores:Atisso C.M., Avezum A.J., Basile J.N., Cardona-Munoz E.G., Chung N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., DIaz R., Franek E., Gerstein H.C., Hâncu N., Hanefeld M., Holt S., Jansky P., Keltai M., Lakshmanan M., Lanas F., Leiter L.A., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:scopusThe association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial
ArticleAbstract: We compared cardiovascular and other outcomes in patients with dysglycaemia with or without anti-gluPalabras claves:anti-GAD, CVD, Type 2 DiabetesAutores:Birkeland K.I., Gerstein H.C., Grill V., Lee S.F., McQueen M.J., PATRICIO LOPEZ -JARAMILLO, Wium C.Fuentes:googlescopus